Fig. 6

In vivo biodistribution of CD38pep- and CD138pep-targeted nanoparticles loaded with pro-drug doxorubicin. Nanoparticles targeted with CD38pep or CD138pep were prepared loaded with a doxorubicin pro-drug, and their in vivo biodistribution was tested against that of free doxorubicin in a subcutaneous xenograft mouse model. Mice were injected with H929 cells, and tumors grew to a predetermined size before IV injection of nanoparticle formulations. 24 h after nanoparticle injection, the mice were perfused, killed, and the tumor and major organs imaged (a, b). Tumors were then digested, and uptake of the nanoparticles to tumor cells was measured via flow cytometry (c). n = 6 for all groups. Data represent means (± s.e.)